| Literature DB >> 27471453 |
Johann du Hoffmann1, Saleem M Nicola1.
Abstract
Dopamine receptor activation in the nucleus accumbens (NAc) promotes vigorous environmentally-cued food-seeking in hungry rats. Rats fed ad libitum, however, respond to fewer food-predictive cues, particularly when the value of food reward is low. Here, we investigated whether this difference could be due to differences in the degree of dopamine receptor activation in the NAc. First, we observed that although rats given ad libitum access to chow in their home cages approached a food receptacle in response to reward-predictive cues, the number of such approaches declined as animals accumulated food rewards. Intriguingly, cued approach to food occurred in clusters, with several cued responses followed by successive non-responses. This pattern suggested that behavior was dictated by transitions between two states, responsive and non-responsive. Injection of D1 or D2 dopamine receptor agonists into the NAc dose-dependently increased cue responding by promoting transitions to the responsive state and by preventing transitions to the non-responsive state. In contrast, antagonists of either D1 or D2 receptors promoted long bouts of non-responding by inducing transitions to the non-responsive state and by preventing transitions to the responsive state. Moreover, locomotor behavior during the inter-trial interval was correlated with the responsive state, and was also increased by dopamine receptor agonists. These results suggest that activation of NAc dopamine receptors plays an important role in regulating the probability of approach to food under conditions of normative satiety.Entities:
Keywords: addiction; extinction; locomotion; mesolimbic; obesity; reward-seeking behavior; satiety
Year: 2016 PMID: 27471453 PMCID: PMC4943936 DOI: 10.3389/fnbeh.2016.00144
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Figure 1D1 and D2 receptor agonists and antagonists, respectively promote and attenuate cued approach to reward. (A) 2CS+ task schematic. Time is not to scale. (B,C) Single session average response ratio (% of cues responded to) in 15 min time bins to cues that predict large (B) and small (C) volumes of 10% sucrose (black line), and the first three (gray) and fourth (orange) days after the switch to equivalent volumes of 3% sucrose reward. (D) Symbols show the mean response ratios to cues that predict 250 μl (“Large”) or 150 μl (“Small”) of 3% sucrose reward after injection of saline (black circles), low (red open squares) and high doses (light red squares) of the D1 receptor agonist SKF 81927, and of the D1 antagonist SCH 23390 (dark red triangles), into the NAc core. The bold lines connect the response ratio data from the first and second hour of the behavioral session. (E) The graph follows identical conventions to those in (D) for injection of saline (black circles), low (blue open squares) and high dose D2 receptor agonist quinpirole (light blue squares) and D2 antagonist raclopride (dark blue triangles) into the NAc core. Error bars in this and all subsequent figures denote SEM. *p < 0.05 compared to saline. See Table 1 for all statistical results. See Methods Section Drugs for drug doses.
Statistical results.
| Figures | Saline | hour | Response (%) | Repeated measures ANOVA | |
| Figures | Saline | cue type | Response (%) | Repeated measures ANOVA | |
| Figures | Saline | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figures | Saline | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figures | Saline | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figures | Saline | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figures | Saline | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | D1 agonist low dose | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist low dose | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist low dose | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist high dose | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist high dose | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist high dose | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D1 antagonist | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D1 antagonist | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist low dose | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D1 agonist low dose | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D1 agonist low dose | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D1 agonist low dose | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D1 agonist low dose | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist low dose | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist low dose | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist low dose | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | D1 agonist high dose | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D1 agonist high dose | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D1 agonist high dose | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D1 agonist high dose | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D1 agonist high dose | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | D1 antagonist | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D1 antagonist | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D1 antagonist | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D1 antagonist | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D1 antagonist | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 antagonist | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 antagonist | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D1 antagonist | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | D1 antagonist | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist low dose | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist low dose | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist low dose | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist high dose | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist high dose | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist high dose | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 antagonist | hour | Response (%) | Repeated measures ANOVA | |
| Figure | D2 antagonist | cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 antagonist | hour × cue type | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist low dose | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D2 agonist low dose | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D2 agonist low dose | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D2 agonist low dose | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D2 agonist low dose | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | D2 agonist high dose | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D2 agonist high dose | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D2 agonist high dose | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D2 agonist high dose | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D2 agonist high dose | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | D2 antagonist | Large 1 h vs. Large 2 h | Response (%) | paired | |
| Figure | D2 antagonist | Small 1 h vs. Small 2 h | Response (%) | paired | |
| Figure | D2 antagonist | Large 1 h vs. Small 1 h | Response (%) | paired | |
| Figure | D2 antagonist | Large 2 h vs. Small 2 h | Response (%) | paired | |
| Figure | Saline vs. D2 antagonist | Large 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 antagonist | Small 1 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 antagonist | Large 2 h | Response (%) | Sidak corrected Welch's | |
| Figure | Saline vs. D2 antagonist | Small 2 h | Response (%) | Sidak corrected Welch's | |
| Figures | All injection types | Count | Pauses in cue responding | One-way ANOVA | |
| Figures | All injection types | Cumulative time (s) | Pauses in cue responding | One-way ANOVA | |
| Figure | Saline vs. D1 agonist low dose | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D1 antagonist | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Drug (s) | Variables | Event | Test | Result | |
| Figure | Saline vs. D1 agonist low dose | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D1 antagonist | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 antagonist | Count | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figure | Saline vs. D2 antagonist | Cumulative time (s) | Pauses in cue responding | Sidak corrected Welch's | |
| Figures | Saline | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D1 agonist low dose | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D1 agonist high dose | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D2 agonist high dose | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D2 agonist low dose | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D2 agonist high dose | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 agonist low dose | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 agonist low dose | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 agonist high dose | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 agonist high dose | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 agonist low dose | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 agonist low dose | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 agonist high dose | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 agonist high dose | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | D1 antagonist | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | D2 antagonist | 1 vs. 2 h | Component 1-Component 2 | Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 antagonist | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D1 antagonist | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 antagonist | 1 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | Saline vs. D2 antagonist | 2 h | Component 1-Component 2 | Non-Paired Wilcoxon signed-rank test | |
| Figure | All injection types | Onset latency (s) | Cued Movement | One-way ANOVA | |
| Figure | All injection types | Latency (s) | Receptacle entry | One-way ANOVA | |
| Figure | All injection types | Efficiency | Cued Movement | One-way ANOVA | F4,27 = 1.19, |
| Figure | saline | Rate in 1 and 2 h | Receptacle entry | Repeated Measures ANOVA | |
| Figure | D1 agonist low dose | Rate in 1 and 2 h | Receptacle entry | Repeated Measures ANOVA | |
| Figure | D1 agonist high dose | Rate in 1 and 2 h | Receptacle entry | Repeated Measures ANOVA | |
| Figure | D2 agonist low dose | Rate in 1 and 2 h | Receptacle entry | Repeated Measures ANOVA | |
| Figure | D2 agonist high dose | Rate in 1 and 2 h | Receptacle entry | Repeated Measures ANOVA | |
| Figure | Saline vs. D1 agonist low dose | Rate (Hz) pre-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist low dose | Rate (Hz) post-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Rate (Hz) pre-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Rate (Hz) post-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Rate (Hz) pre-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Rate (Hz) post-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Rate (Hz) pre-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Rate (Hz) post-cue | Receptacle entry | Sidak corrected Welch's | |
| Figure | saline | ITI length (10 s bins) | Response (%) | Repeated measures ANOVA | |
| Figure | D1 agonist high dose | ITI length (10 s bins) | Response (%) | Repeated measures ANOVA | |
| Figure | D2 agonist high dose | ITI length (10 s bins) | Response (%) | Repeated measures ANOVA | |
| Figure | Saline | Path length (cm) | Response type | Repeated measures ANOVA | |
| Figure | D1 agonist low dose | Path length (cm) | Response type | Repeated measures ANOVA | |
| Figure | D1 agonist high dose | Path length (cm) | Response type | Repeated measures ANOVA | |
| Figure | D2 agonist low dose | Path length (cm) | Response type | Repeated measures ANOVA | |
| Figure | D2 agonist high dose | Path length (cm) | Response type | Repeated measures ANOVA | |
| Figure | Saline vs. D1 agonist low dose | Path length (cm) | Trials with a response | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist low dose | Path length (cm) | Trials with no response | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Path length (cm) | Trials with a response | Sidak corrected Welch's | |
| Figure | Saline vs. D1 agonist high dose | Path length (cm) | Trials with no response | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Path length (cm) | Trials with a response | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist low dose | Path length (cm) | Trials with no response | Sidak corrected Welch's | |
| Figure | Saline vs. D2 agonist high dose | Path length (cm) | Trials with a response | Sidak corrected Welch's |
Each row describes one statistical comparison using the data in the graph indicated by “Figure.” “Drugs” describes the drug condition(s) being compared (an entry of an individual drug means that the comparison is made only with data obtained after injection of that drug); “Variables” and “Event” together describe the measures being compared; “Test” names the statistical test used, and “Result” provides the results of the test.
Figure 2D1 and D2 receptor agonists decrease time spent in the non-responsive state. (A–E) Rasters show five example sessions, one for each drug (high doses only). Each line represents the time at which a cue predicting large (black) or small reward (orange) was presented. The top raster of each pair indicates cues that the animal responded to by entering the receptacle. The bottom raster indicates cues that the animal did not respond to. Note that the length of the non-responsive state is longer toward the end of the session in the control condition (A), but the non-responsive state is very short or absent in the D1 agonist (B) and D2 agonist (C). (F) The left graph plots cumulative time spent in the non-responsive state against the number of transitions from responsive to non-responsive. Thus, steeper lines indicate long pauses (non-responses to contiguous sequences of cues) interrupted with few responses and shallower lines represent short pauses with frequent responses. Each line is the data from an individual rat. The bar plots on the right show the mean cumulative time spent in a non-responsive state over the entire session for each treatment group. Color conventions are identical to those in Figure 1D. (G) The graphs follow identical conventions to those in (F), but here for the D2 agonist and antagonist treatments. Color conventions are the same as those in Figure 1E. *p < 0.05.
Figure 3Schematic of a two-state Markov model. On a given trial, a rat can either stay in the responsive (left circle and looping arrow) or non-responsive state (right circle and looping arrow) or transition to the other state (arrows between the circles). Each of these events occurs with a probability that is calculated by classifying all trials as those in which the animal responded (R+) and did not respond (R−), and then classifying the next trial in the same way. This procedure results in 4 possible categories for any consecutive pair of trials: R+,R+; R+,R−; R−,R−; and R−,R+. The probability of the second trial outcome given the first is determined with the equation P( = N( / N(, where N is the number of trials. The 4 categories that describe the possible behaviors in any pair of trials form a stochastic matrix. We resolved this matrix into steady state probability vectors, which yield an estimate of the probability of finding each subject in either the responsive or non-responsive state at a steady state of the Markov chain.
Figure 4D1 and D2 receptor agonists promote transistions from the non-responsive to responsive state. (A,C,F,H). These graphs show the associated transition probabilities for all 4 possible response/no response pairs, calculated with the equation given in the legend to Figure 3. (A) The dots represent the transition probabilities in the first hour of behavioral testing for saline (black), high dose D1 agonist (red) and high dose D2 agonist (blue) treated rats. Note that in this first hour there is a very high probability of responding to a cue if the rat responded to the previous cue; this is indicative of response clustering. (B) The dots represent the cross-session mean of the components of the probability vectors calculated from the transition matrices that compose the mean probabilities in (A). The two components give a steady state estimate of the probability of the rats being in the high (“High,” left dots) and low (“Low” right dots) responsive state, respectively. D1 agonist data is almost completely obscured by the D2 agonist data. (C,D) This data comes from the same sessions as in (A,B), but the data is taken from the second hour of testing. (E) Dot plots show the median and middle quartiles of the differences between the two components of the probability vectors that are shown in (B) (left set of dot plots) and (D) (right dot plots). Filled symbols represent saline and high agonist doses. Open symbols represent low agonist doses (corresponding data in (A–D) are not shown for low doses). (F–J) Same plotting conventions as in (A–E), but these figures show data from the first (F,G) and second hour (H,I) after saline (black), D1 antagonist (dark red) and D2 antagonist (dark blue) injections. *p < 0.05.
Figure 5The dopamine agonists increase locomotion, but increased cue responding is not attributable to increased locomotion. (A) The left group of bars shows the effects of injection of saline, D1 and D2 agonists on the mean latency to initiate movement after cue onset, and the right group shows the mean latency to reach the receptacle. Color conventions are the same as in Figures 1D,E. (B) Path efficiency (a measure of directness of approach to the receptacle) was not affected by either agonist or saline. (C) The mean rate of receptacle entry 5 s before (left group of bars) and during cue presentation (right group) for trials with a behavioral response. (D) The mean response ratio (%) for different ITI lengths (bin width = 10 s) after saline (black), D1 agonist (light red) and D2 agonist (light blue) injection. The probability of a cued response was not significantly correlated with ITI length in any of the treatment groups. (E) The bars show the mean rate of locomotion during ITIs when rats respond (left group of bars) and do not respond (right group) to the subsequent cue. *p < 0.05, +p < 0.1.
Figure 6Histological reconstruction of injection sites. Figure depicts two coronal sections of rat brain that encompass the majority of the anterior-posterior extent of the NAc (0.8–2.8 mm anterior from Bregma). Black dots represent estimates of the location of microinjections for each animal.